Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.

Abstract: Variants of chymosin with improved milk-clotting properties are disclosed.

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Abstract: A method of calibration of a system designed for analysis of ground reaction forces of a user's feet, wherein the system comprises a left and right footwear each with a plurality of force sensors. The method includes (a) obtaining respective data measurements from each force sensor over a time period while the user's feet are in the left and right footwear; (b) determining a respective statistic of the respective data measurements for each force sensor over the time period; and (c) storing the respective statistic as a respective calibration offset for a respective force sensor. The respective statistic may comprise a minimum, a maximum, an average, a median, a percentile, and/or a statistical model of the respective data measurements.

Abstract: Brackets for mounting auxiliary suspension systems, such as lift axle systems, to vehicles are disclosed herein. For example, brackets are disclosed for attaching lift axle hanger brackets and lift axle load springs to corresponding frame members. In some embodiments, the frame brackets can include physical features (e.g., a series of graduated steps in an edge portion thereof) to facilitate visual alignment of the lift axle with the vehicle frame members during installation. In other embodiments, the frame brackets can be two-piece brackets that enable the load springs to be removed and replaced without having to detach the frame bracket from the frame rail.

Abstract: A computer-implemented method of operating a mobile communication device includes attaching the mobile communication device to a first cellular network, and while the device is attached to the first cellular network: calculating a first quality of service of the first cellular network, for each of a plurality of other available cellular networks, estimating a quality of service thereof, and if the calculated first quality of service is lower than a pre-determined threshold value representing a minimally acceptable quality of service and the estimated quality of service of at least one of the plurality of other available cellular networks is higher than the first quality of service: detaching the device from the first cellular network, and attaching the device to a second cellular network among the at least one of the plurality of other available cellular networks that has an estimated quality of service higher than the first quality of service.

Abstract: A system for and method of determining anticipated voyage costs are provided. The system and method utilize a plurality of voyage simulations to determine cost information for each simulation. The voyage simulations utilize a digital twin model of a vessel, anticipated routes for the vessel, and weather data associated with each route. The results of the simulations are used to generate statistical probability for anticipated costs for a voyage, thereby facilitating more accurate predictions of costs that can be used to assess voyage feasibility and profitability.

Abstract: The conveyor system comprises a frame (2) with a substantially plane conveying surface composed by rollers (3) for conveying products (P) in a conveying direction T to an end station with end stop (8); —wherein the frame (2) comprises an edge part with roller shaft slots (5) each with a roller shaft slot lower end, in which roller shafts (4) are displaceably received; —wherein the conveyor system further comprises a beam (6) with a drive belt (7) arranged against the rollers (3) for rotating the rollers (3) to thereby convey the products (P), in particular such that upon a product (P) reaching the end stop (8) or upon a product (P) reaching a preceding arrived product (P) said drive belt (7) slips under the rollers (3) under these arrived products (P); and —wherein the conveyor system is configured such that a maximum pushing force which buffers these products (P) is obtained.

Abstract: An electron beam inspection apparatus, the apparatus including a plurality of electron beam columns, each electron beam column configured to provide an electron beam and detect scattered or secondary electrons from an object, and an actuator system configured to move one or more of the electron beam columns relative to another one or more of the electron beam columns, the actuator system including a plurality of first movable structures at least partly overlapping a plurality of second movable structures, the first and second movable structures supporting the plurality of electron beam columns.

Abstract: The invention relates to a method of MR imaging of an object (10) positioned in an examination volume of a MR device (1). It is an object of the invention to enable efficient and high-quality non-Cartesian MR imaging, even in situations of strong B0 inhomogeneity. In accordance with the invention, the method comprises: —subjecting the object to an imaging sequence comprising at least one RF excitation pulse and modulated magnetic field gradients, —acquiring MR signals along at least one non-Cartesian k-space trajectory, —reconstructing an MR image from the acquired MR signals, and —detecting one or more mal-sampling artefacts caused by B0 inhomogeneity induced insufficient k-space sampling in the MR image using a deep learning network. Moreover, the invention relates to a MR device (1) and to a computer program.

Abstract: The present invention relates to compositions, methods, and kits for predicting a subject's response to a CAR T cell therapy, by analyzing the intestinal microbiome of the subject. The present disclosure also provides a method of detecting patients at risk for a poor response to CAR T cell therapy by measuring the level of the presently disclosed bacteria or bacterial genes in the microflora or microbiome of a patient receiving or considered for CAR T cell therapy. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, by improving the subject's response to a CAR T cell therapy.

Abstract: The present invention relates to methods and compositions for reducing the risk of cancer relapse in a subject who has received cancer treatment. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Streptococcus anginosus, Parvimonas micra, Acidaminococcus intestini, Eubacterium limosum, Clostridium glycyrrhizinilyticum, Desulfosporosinus lacus, Eubacterium biforme, Anaerofustis stercorihominis, Pseudoramibacter alactolyticus, Peptococcus niger, Armatimonas rosea, Saccharofermentans acetigenes, Finegoldia magna, Levyella massiliensis, Gallicola barnesae, Murdochiella asaccharolytica, and Eubacterium brachy are associated with a reduced risk of cancer relapse.

Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Abstract: Variants of chymosin with improved milk-clotting properties are disclosed.

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.